Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial to compare intra-gastric injection of Botulinum Toxin A
(Botox; Allergan Inc. Irvine, Ca, USA) against non-surgical management for obesity (i.e.
exercise/diet). Our hypothesis is that intra-gastric injection of Botox into the fundus and
body of the stomach will result in greater weight loss than just exercise and diet alone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tan Tock Seng Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A